Imagine a world where a simple shift in perspective could unlock new possibilities for treating a deadly disease. That's exactly what researchers at Penn State have discovered, and it's a game-changer for leukemia patients.
Two drugs, originally designed to tackle prostate cancer, have shown remarkable potential in fighting leukemia. But here's where it gets controversial: these drugs, apalutamide and finasteride, have been approved by the FDA for prostate cancer, but their effectiveness against leukemia was an unexpected find.
The study, published in Blood Advances, tested these drugs on experimental models, including mice and patient-derived AML cells. The results were astonishing. Both drugs successfully suppressed AML progression in male and female mice, indicating a promising new direction for treatment.
Dr. K. Sandeep Prabhu, a lead author on the paper, explained that these drugs work by targeting a specific pathway activated by dihydrotestosterone, a potent androgen hormone. While androgen signaling has been well-studied in prostate cancer, its role in AML has been largely unexplored until now.
"In our study, these drugs effectively treated AML, highlighting their potential for new uses," Prabhu said.
Professor Robert Paulson, another co-author, emphasized the significance of this discovery: "AML is a challenging disease, and finding a new target like the androgen receptor, where FDA-approved drugs already exist, is incredibly exciting. The next step is clinical trials, and we're eager to see the impact on patients."
And this is the part most people miss: the connection between leukemia and androgen receptors was previously unknown. Fenghua Qian, a senior scientist at Regeneron and lead researcher on the study, stumbled upon this discovery while working on an AML mouse model.
Qian noticed that female mice had a lower chance of developing AML, even without ovaries and estrogen. This led him to analyze the role of androgen, and he found that androgen receptors were highly expressed in female donor leukemic cells.
In the current study, researchers found that high dihydrotestosterone in male mice promoted AML, despite low androgen receptors in their leukemia cells. Conversely, female mice with low dihydrotestosterone had high levels of androgen receptors, which also held true for AML cells from human patients.
Finasteride slowed AML progression by inhibiting dihydrotestosterone, while apalutamide targeted a slightly different pathway in androgen receptor activity.
Qian believes this study opens up a novel targetable pathway for leukemia patients, potentially benefiting those resistant to traditional treatments.
"Androgen receptors and their interactors could be a direct target for treatment," he said.
While the study is promising, the researchers emphasize the need for further testing, including clinical trials on leukemia patients with specific criteria, such as increased androgen receptor expression in leukemic cells.
Dr. Prabhu highlights the importance of attention to detail, crediting Qian's vigilance for this groundbreaking discovery.
"Qian's keen observation and presence of mind caught something that changed everything," Prabhu said.
So, what do you think? Could this be a turning point in leukemia treatment? We'd love to hear your thoughts in the comments!
